Goldman Sachs analyst Andrea Tan maintained a Buy rating on Codiak BioSciences (CDAK – Research Report) today and set a price target of $8.00. The company’s shares closed last Tuesday at $2.98, close to its 52-week low of $2.50.
According to TipRanks.com, Tan is ranked 0 out of 5 stars with an average return of -34.5% and a 0.0% success rate. Tan covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Kodiak Sciences, and Vor Biopharma.
Currently, the analyst consensus on Codiak BioSciences is a Moderate Buy with an average price target of $8.00.
Codiak BioSciences’ market cap is currently $64.78M and has a P/E ratio of -1.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Read More on CDAK: